Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_assertion type Assertion NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_head.
- NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_assertion description "[Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_provenance.
- NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_assertion evidence source_evidence_literature NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_provenance.
- NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_assertion SIO_000772 18344568 NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_provenance.
- NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_assertion wasDerivedFrom befree-2016 NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_provenance.
- NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_assertion wasGeneratedBy ECO_0000203 NP660954.RAC2P9VuXBRne9N-7-L65RPNHANoLTqvnQIB0o3DDgJ6M130_provenance.